ASPIVIX closes Series A+ funding round with USD 5 million and wins EUREKA-EUROSTARS grant

ASPIVIX, a medical technology company focused on innovations in women’s healthcare is the maker of the new generation of non-traumatic cervix stabilizer CAREVIX™. The company announced today that it has raised USD 5 million in a Series A+ funding round. The round was led by HEMEX and was joined by existing investors 4FOx ventures and Zürcher Kantonalbank, as well as new investor LaunchPad APAC.

ASPIVIX will use this new investment to enter the market in Europe and US. Additionally, the company will invest in R&D to expand its existing product line and generate additional clinical data in the US. This will allow Aspivix to continue giving women gentler and safer access to gynecological procedures and contraception. 

The EUREKA-EUROSTARS grant, which is co-funded by the Swiss innovation agency Innosuisse, will enable ASPIVIX to invest in new product development and sharpen its technological edge. "This grant will allow ASPIVIX to boost our research and materialize our goal for a gynecology, now modern!” explained Julien Finci, co-founder and CTO. 

ASPIVIX aims to provide women with gentler and safer gynecological procedures with its clinically tested technologies. "The trust from our existing and new investors is a great motivation to realize our vision in women’s health and make a difference for millions of women worldwide," co-founder and CEO Mathieu Horras stated.

"We are very impressed with the excellent clinical outcomes ASPIVIX has demonstrated with CAREVIX™ in gynecological procedures like intra-uterine device (IUD) insertion,” adds Pascal Winnen, CEO of HEMEX AG and new Board Member at ASPIVIX. "We believe that the significant reduction in pain and bleeding will allow many more women to choose this safe and efficacious method of contraception."

ASPIVIX was awarded CHF 130,000 by Venture Kick in 2018. The startup was also chosen to take part in the Venture Leaders Life Sciences program in 2018 (now split into Medtech and Biotech), which takes innovators to Boston to meet investors and industry experts to accelerate their growth on the global stage. In 2020, the company was named one of the TOP 100 Swiss Startups.

ASPIVIX co-founder Mathieu Horras stated: "How do you get a boost to kick your idea and turn it into a company? How do you connect with investors, leaders, and like-minded entrepreneurs? How do you expand to promising markets, and how do you get the visibility and recognition you deserve among the TOP 100 Swiss Startups? These are typical questions entrepreneurs have. There is one answer to all these questions: Venture kick and Venture Leaders programs! We are grateful for this continuous support, materializing today with this Series-A+."

ASPIVIX founders Julien Finci (CTO) and Mathieu Horras (CEO). The funding will allow ASPIVIX to bring its product, CAREVIX, to market. The suction-based cervical device has been clinically proven to reduce pain and bleeding during transcervical procedures without compromising on performance.